Company intelligence
Benno Therapeutics
Developing a Novel Treatment of Urothelial Cancer of the Bladder in Dogs
Biotechnology Research
HEVERLEE, BE
4 employees
Founded 2024
4 public signals
About Benno Therapeutics
Cancer is a leading cause of death in dogs, just as it is in humans. At Benno Therapeutics, we have found ways to significantly increase survival rates, without the typical side-effects of more traditional cancer treatments. Listen to our story on Spotify or Apple Music (search for Benno's song)
Verified activity
Signals from Benno Therapeutics
4 published signals
Research & Knowledge
Benno Therapeutics is starting research into a cancer vaccine for cats at Ghent University.
Reported by Benno Therapeutics
Research & Knowledge
Benno Therapeutics is launching a proof-of-concept study in dogs with urothelial carcinoma, hemangiosarcoma, osteosarcoma, and oral melanoma, supported by Ghent University and veterinary clinic networks across Flanders.
Reported by Benno Therapeutics
Operations & Supply
Benno Therapeutics is manufacturing its therapeutic cancer vaccine for companion animals on two parallel tracks, including E. coli-based GMP production with specialised partners and a plant-based route supported by VLAIO - Flanders Innovation & Entrepreneurship.
Reported by Benno Therapeutics
Capital & Finance
Benno Therapeutics closed its financing round and moves from development into manufacturing and clinical validation of its therapeutic cancer vaccine for companion animals.
Reported by Benno Therapeutics